User Notice: The old Support number is no longer in use. To reach Support please call +44 (0) 203 8794 460

Share Name Share Symbol Market Type Share ISIN Share Description
Proteome Sciences Plc LSE:PRM London Ordinary Share GB0003104196 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 3.75 18,415 16:35:26
Bid Price Offer Price High Price Low Price Open Price
3.50 4.00 3.50 3.50 3.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 3.41 -1.66 -0.44 11.0
Last Trade Time Trade Type Trade Size Trade Price Currency
16:13:36 AT 16,215 3.50 GBX

Proteome Sciences (PRM) Latest News

More Proteome Sciences News
Proteome Sciences Takeover Rumours

Proteome Sciences (PRM) Share Charts

1 Year Proteome Sciences Chart

1 Year Proteome Sciences Chart

1 Month Proteome Sciences Chart

1 Month Proteome Sciences Chart

Intraday Proteome Sciences Chart

Intraday Proteome Sciences Chart

Proteome Sciences (PRM) Discussions and Chat

Proteome Sciences Forums and Chat

Date Time Title Posts
15/7/201918:02Proteome Sciences leading Alzheimer's technology.82,846
12/7/201917:42Proteome, what next? (moderated)55,102
02/7/201917:54The useful PRM thread13
13/2/201918:56The 2008 PRM Golf Day Thread39
07/9/201812:25PRM - Charlie Bore, what does he add?6

Add a New Thread

Proteome Sciences (PRM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-07-15 15:13:363.5016,215567.53AT
2019-07-15 08:53:433.502,20077.00O
View all Proteome Sciences trades in real-time

Proteome Sciences (PRM) Top Chat Posts

Proteome Sciences Daily Update: Proteome Sciences Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker PRM. The last closing price for Proteome Sciences was 3.75p.
Proteome Sciences Plc has a 4 week average price of 2.81p and a 12 week average price of 2.58p.
The 1 year high share price is 4.24p while the 1 year low share price is currently 2.22p.
There are currently 294,648,723 shares in issue and the average daily traded volume is 37,801 shares. The market capitalisation of Proteome Sciences Plc is £11,049,327.11.
up10: This recent Randox announcement is big news and will see the share price go significantly higher. Remember, the annual market for a Stroke blood test is in excess of $1 Billion and Proteome Sciences receives double digit royalties. Do the maths, PRM's share price will move much much higher.
saul goodman: bluemango Posts: 1 Opinion: Weak Buy Price: 0.00 PRM7 Jan '10 These shares have had a very volatile history, in common with many stocks in the UK biotech sector, and PRM has a history of raised expectations but poor delivery. This situation now looks to be changing with the first diagnostic tests using Proteome's biomarkers coming on the market, (e.g. a lung cancer diagnostic test due for UK launch this year), but it has been a long while coming. If they can grab a good share of the market in diagnostic biomarkers for diseases such as Alzheimer's and cancer, then the growth in revenues and market value could be spectacular, BUT there have been many false dawns before with this company, and for most observers it is still 'believe it when I see it'. Personally I'm confident those rewards will come, possibly with many times the current share price, but it has been a long slog getting to the point of commercial revenues. Breakeven this year would be a significant achievement and could be the start of some seriously significant growth for this company BUT this is one risky share ...... so beware, and be prepared to be patient ....
jeffian: Blimey, say! Quite a few lessons to be learned there but this one caught my eye in particular - "He listed some of the difficulties ahead, and indicated that he considered the PRM share price already to be too high. I started to write out an answer to all his points. But I suddenly remembered a lesson I learned many years ago – that it is not wise to argue with a scientist. So I gave up the task and just simply bought more PRM shares instead."
ih_433513: Happy 10 year anniversary wasJobber. You were a busy boy! wasjobber - 02 Jul 2008 - 22:49:36 - 3909 of 16188 Proteome Sciences - from research to revenue in 07 - PRM The reasons and terms of cjp's loan to the company are being twisted out of all proportion on this bb to benefit the bashers/shorters positions. Most if not all comments on here relating to this and many other issues are false! wasjobber - 02 Jul 2008 - 20:52:20 - 36923 of 54056 Proteome, what next? (moderated) - PRM monte1 So thats your only reason to continually bash the stock and try to cause weaker holders to sell is it? It's not logical i'm afraid to be selling prm when they are at last on the cusp of generating significant revenue. It's pathetic to try and kid people you own prm stock yourself by the way. wasjobber - 02 Jul 2008 - 20:06:23 - 36920 of 54056 Proteome, what next? (moderated) - PRM monte1 As you seem to be one of the more vocal bashers on here, maybe you can tell me how the company is in a poorer situation now than say 1 or 2 years ago? With the Thermo deal done (providing growing income) and other deals now much closer! wasjobber - 02 Jul 2008 - 17:32:09 - 36916 of 54056 Proteome, what next? (moderated) - PRM Funny how the bashers go so quiet after office hours. wasjobber - 02 Jul 2008 - 17:29:43 - 36915 of 54056 Proteome, what next? (moderated) - PRM the_doctor, Sorry but that simply doesn't make sense to me! PRM are in a far far better position now, even with £6m debt. Which of course will be wiped out by cjp converting or other income. wasjobber - 02 Jul 2008 - 17:14:15 - 36911 of 54056 Proteome, what next? (moderated) - PRM I suppose my last post is just far to sensible for most people on here. wasjobber - 02 Jul 2008 - 17:06:12 - 36909 of 54056 Proteome, what next? (moderated) - PRM loftybob, I'm refering to the_doctor answering my earlier question! The situation now is far better now than 1 or 2 years ago! Massive Thermo deal, other huge prospects. If the situation is worse now then please explain, because i can't see it! wasjobber - 02 Jul 2008 - 16:59:23 - 36906 of 54056 Proteome, what next? (moderated) - PRM the_doctor ? wasjobber - 02 Jul 2008 - 16:45:38 - 36899 of 54056 Proteome, what next? (moderated) - PRM the_doctor I must be very stupid. Why is the company any more like to go bust now than say 1 or 2 years ago? Pearce is very happy to fund the company until it is in profit! wasjobber - 02 Jul 2008 - 16:18:11 - 36889 of 54056 Proteome, what next? (moderated) - PRM dwschag, Some sense on here at last! wasjobber - 02 Jul 2008 - 16:03:08 - 36878 of 54056 Proteome, what next? (moderated) - PRM loafingchard, I'm here and a raging bull, BUY, BUY, BUY. The share price is just bloody silly. wasjobber - 02 Jul 2008 - 12:57:57 - 36784 of 54056 Proteome, what next? (moderated) - PRM;cb=1214999844&article=7325098&symbol=L%5EPRM wasjobber - 02 Jul 2008 - 12:52:57 - 36781 of 54056 Proteome, what next? (moderated) - PRM Thermo will be bidding shortly, just watch! wasjobber - 02 Jul 2008 - 11:31:51 - 36763 of 54056 Proteome, what next? (moderated) - PRM Bid coming! wasjobber - 02 Jul 2008 - 09:30:09 - 36730 of 54056 Proteome, what next? (moderated) - PRM silentaction, PRM won't go like that, it's impossible with CJP's protection of IP.
saul goodman: Hahahahahaha - I note that it is 1999 all over again on iii! 10:36 John Hopkins Cancer Test "breakthrough"...i network This present news headline sounds like it depends on proteomics tests as well as genetic tests. I would think this could have significant impact on proteomic testing sales and services/ Why is this not affecting PRM share price?? ---------------------------------------------------------------------------------- 12:30 Hold Re: John Hopkins Cancer Test The Potter I also recently read an article on Sepsis, where biomarkers were found to give the best indication of the presence of this illness. I suppose that the share price Is unaffected by these news items, because many investors do not understand the possible implications, and those that do, are awaiting for news of profitability (promised in 2018). TP
pools2: With Proteome Sciences now a GCLP accredited company, many many more doors are now open to them, which were firmly closed before. Do not underestimate the significance of the new accreditation and the additional business it will bring. PRM share price will go up and up from this current level. No additional funding will be needed and the company will be in profit next year.
tyum: BUY BUY BUY PRM share price is going up from here. Good news is coming. Buy at 4p while you can.
badger60: No they don't. People are far more interested about your cartel's intention to use questionable market manipulation to ramp up the PRM share price.......
dunderheed: Good evening gentlemen. Whilst we call await becoming millionaires in line with prm share price may I suggest a competition to guess the share price on 31.12.2017. I am coming kn with a possibly optimistic 54 gpb. I base this on a hypothesis that a deal it t/o is likely to happen with a large American company later in the year. I don't want to give too much away but I think the letters G and E are included in the name of company. All imho. Jt could you add this message to the header and maybe start a list of suggested share prices please? Thanks very much and have a Good night all.
saul goodman: This beaut is from 8 years ago to the day: (Name withheld in order to reduce acute embarrassment to anyone associated with the avatar) 9 May '09 - 09:48 - 47364 of 53733 0 0 PRM Summary - 8 May 09 [ Posted particularly to answer the question from MS MS regarding what happened on 13 Nov 2007?]. BACKGROUND. (This is a condensed summary of more than 50 pages of detailed research which I consider provides proof that the following explanation of the importance of 13 November 07 is correct.) We know, from the specific reference to strategic alliances in the Annual and Interim Reports in 2002, 2003 and 2004 and the related events beginning in the spring of 2003, that PRM had first a partnership with Amersham (for the Sensitizer, which was originally expected to make PRM profitable in 2003) and then a major strategic alliance (secret NDA) with GE which came into effect on completion of their takeover of Amersham in April 04. That strategic alliance resulted in GE taking over the commercialisation of PRM’s IP (in GE’s name) on the basis that GE would make a takeover offer - for which PRM would recommend acceptance – immediately PRM became profitable which was then confidently expected the following month. The price at which the takeover offer would be made would be based on GE’s standard formula for companies which had not yet become profitable – namely X3 the average share price over the preceding 3 years. That was arranged in December 2003 when the PRM share price was already well over £2 and expected to rise sharply before they became profitable and so to have resulted in a bid at the agreed value of around £5. But those plans were stymied in early May 04 by the ABI announcement of their iTRAQ which led to a patent issue which, in turn, led to the subsequent delays. That patent issue only became finally due to be settled on 13 November 2007 with the grant of the US TMT patent on that date. Meanwhile, the confident tone of PRM’s Reports suggested that GE has been making good progress with the commercialisation of PRMs IP. But PRM, bound by the secrecy clause in their strategic alliance NDA, was not (and is still not) allowed to announce details of that progress. In consequence the lack of real news (for several years) had resulted in the share price continuing at such a small fraction of PRM’s increasing value that (to protect its shareholders from a very low takeover price) PRM had no option but to delay PRM becoming profitable. Meanwhile, the progress on developing the value of PRM’s IP, with GE’s assistance, was steadily further increasing PRM’s value above that £5 level – as indicated on the PRM website with several products moving from “long term” towards “near term” and by the grant of the 350 patents etc mentioned in the PRM Reports. The planned TMT licence deal was with GE, who had already arranged a sub licence with Thermos Fisher (which had its origins in the deal being negotiated with Thermo Electron by Amersham in late 2003). That direct licence deal would have made PRM profitable on 13 November 2007 and triggered the agreed takeover offer bid. But the low share price meant that offer would have been below £2 per share compared with around the £5 per share originally agreed and intended - but which many shareholders would have accepted, even without PRM being compelled, by the original NDA, to recommend it. [Few shareholders seem to have taken advantage of the excellent estimates by xxxxxxx of the value to PRM of the various parts of its IP, or of the Summaries I posted of them. Many posters appear still to remain completely ignorant of where the share price should be in relation to PRM’s increasing value.] Around November 2007 our CEO, in a reported statement, assessed the value of PRM at nearly £14 per share. BUT because of his agreement to that takeover price formula in the original NDA, PRM would have had to recommend a takeover share price of under £2. That deal was NOT completed. .. WHY NOT? Our CEO was reported to have said that he hoped that shareholders would be pleased with the deal he had done instead It seems obvious that our CEO had managed to persuade GE to amend the original NDA to release PRM from GE’s stranglehold of the original takeover terms agreed four years previously – but still, I now believe, leaving the PROFITABILITY deadline in place to trigger the BIG announcement I have forecast. ----------------------- That, MS MS, is the answer to your question. Events on 12/13 November 2007 dramatically altered the future for us shareholders. We are now assured of a takeover at a price at least £5 per share and probably nearer double that. Meanwhile, as I have already recently posted, the loan conversion provides the directors with the potential ability to hold 29.74% (FD by all options etc) which together with friends appears to amount to around 53% control of PRM. That means that our CEO can now dictate the takeover terms and has a poison pill against low bids. As regards PRM’s finances, anyone who thinks there is, or ever has been, any real problem needs their head examined. You may perhaps ask: “What was that deal that our CEO did with GE?” To anyone who has not done very detailed research on all the events over the last seven years, it may be difficult to guess. But the recent amendments to the PRM website have, as I recently posted, confirmed that my guess about that new deal has been correct. But I do not think that PRM and GE would like it publicised at this time. I will however point out that (as is indicated by PRM apparently not even yet accepting the full down payment on signature from the TF) PRM appear STILL to be doing their best to delay becoming profitable. That accounts for the delays of the last many months – during which the PRM value has continued increasing since his reported statement. The future for PRM looks brilliant I confidently repeat that I believe £5 per share is now a guaranteed minimum. I again confirm that none of my information on which I base all the above has come from either GE or PRM – other then what has been already in the public domain. I also stress that all above is IMO and that you must DYOR Regards to all LTHs, xxxxx PS Edited 25 June 09.
Proteome Sciences share price data is direct from the London Stock Exchange
Your Recent History
Proteome S..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190715 23:56:40